What is Chardan Capital’s Estimate for STOK FY2025 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Chardan Capital upped their FY2025 EPS estimates for shares of Stoke Therapeutics in a report issued on Wednesday, May 14th. Chardan Capital analyst R. Li now forecasts that the company will post earnings per share of $0.45 for the year, up from their prior estimate of ($1.75). Chardan Capital currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million.

STOK has been the topic of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. HC Wainwright lowered their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Finally, Cantor Fitzgerald raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Wednesday, May 14th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $23.20.

Stoke Therapeutics Trading Up 1.3%

Shares of NASDAQ STOK opened at $9.76 on Monday. The firm has a market cap of $532.87 million, a P/E ratio of -4.65 and a beta of 1.20. The business’s 50 day moving average is $8.16 and its 200-day moving average is $9.94. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $17.58.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,532 shares of company stock worth $143,332. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Stoke Therapeutics by 0.9% in the 1st quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock valued at $904,000 after purchasing an additional 1,148 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after acquiring an additional 1,149 shares during the last quarter. Bank of New York Mellon Corp grew its position in Stoke Therapeutics by 1.4% in the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock valued at $1,028,000 after acquiring an additional 1,330 shares during the last quarter. Graham Capital Management L.P. raised its stake in Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after acquiring an additional 1,453 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in shares of Stoke Therapeutics by 2.0% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after acquiring an additional 1,791 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.